INTRODUCTION
STUDY GOAL AND OBJECTIVES
This study provides a comprehensive analysis of emerging
angiogenesis regulating technologies and the impact they will have on the
treatment of disease. The report focuses primarily on angiogenesis inhibitors in
development for cancer treatment and angiogenesis stimulators in development for
the treatment of coronary artery disease and peripheral artery disease. However,
information also is provided on other diseases for which angiogenesis regulation
may be applicable, including autoimmune diseases, dermatological disorders,
ocular diseases and wound healing. Forecasts for the overall angiogenesis
regulation market are provided. Forecasts and trends are gleaned from industry
sources as well as from considered assessment of this innovative technology.
REASONS FOR DOING THE STUDY
The regulation of angiogenesis, the development of blood
vessels, is an area of much activity and promise. The blocking of angiogenesis
is a quickly advancing strategy in the treatment of cancer, inflammatory and
dermatological diseases and eye disorders. By blocking the formation of blood
vessels in tumors, tumor growth is limited to pinhead-size lesions and
metastasis is prevented. The stimulation of angiogenesis is under investigation
as a way of replacing blocked blood vessels in the heart and peripheral
arteries. Angiogenesis stimulation also is under study for enhancing wound
repair.
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
This report explains the angiogenesis process and the
technologies involved in its regulation. It offers information needed to
understand the impact of angiogenesis-regulating products on disease treatment,
as well as how these agents will fit into clinical protocols. It is an
invaluable tool for business planners, acquisitions specialists, licensing
strategists, product managers, market research analysts, investor consultants
and anyone interested in angiogenesis regulation, its products, its industry
participants and its future.
SCOPE AND FORMAT
This report primarily focuses on products in development to
treat cancer and cardiovascular diseases, with discussions of selected products
directed at other diseases.
The competitive environment is examined with a special focus
on how new products and technologies will likely be used in the treatment of
cancer and cardiovascular diseases, i.e., will these products be used as
adjuncts to, or replacement therapy for currently available products and
procedures. Profiles of companies in the late stages of development of
angiogenesis-regulating products are provided.
Market figures are based on revenues at the manufacturers'
level and are projected at 2001 dollar value, i.e., inflation is not computed
into the projection figures. Trends are assessed based on projected product
sales and must necessarily be estimates, since the timing of introduction and
cost of these agents is not certain. Also included in this report are forecasts
through 2006, including supporting analyses for projections.
METHODOLOGY
Information for preparing this study was derived from data
supplied by product managers, marketing strategists, research executives and
others at leading companies involved in the development of angiogenesis
regulating agents. Data was accessed from government agencies and regulatory
bodies that monitor and/or regulate pharmaceutical products. Searches of
secondary material such as company annual reports and 10-Ks, journal articles,
prospectus assessments, government resources and data from health care
institutions also were conducted.
INFORMATION SOURCES
Information for this report was obtained from companies,
organizations and institutions involved in the development of angiogenesis
regulating agents, industry analysts, health care personnel, The Angiogenesis
Foundation, the National Cancer Institute, the American Cancer Society, the
American Heart Association, the Centers for Disease Control and Prevention and
other government agencies, as well as from literature searches, annual reports,
10-Ks and product literature.
View Cart
